DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI - DISCOVERED THERAPEUTIC CANDIDATE
Artificial Intelligence enables target and drug candidate to be identified in less than 18 months. Initial target of Wilson disease represents significant clinical need, new era of drug discovery.
Toronto, Ontario – September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.
“This is ...
DEEP GENOMICS PLANS FOR CLINICAL INNOVATION, APPOINTS PETER BARTON HUTT AS STRATEGIC ADVISOR
Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company as a Strategic Advisor.
Toronto, Ontario – June 26, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company ...
DEEP GENOMICS APPOINTS JAMES DOWLING AS CHIEF MEDICAL OFFICER
James Dowling, M.D., Ph.D. is joining the leadership team at Deep Genomics as Chief Medical Officer. Jim's understanding of patient needs combined with expertise on rare disease biology is crucial to guide the design of AI systems to accelerate clinical development.
Toronto, Ontario – June 24, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that James Dowling, M.D., Ph.D., is joining the team as Chief Medical Officer, effective today.
“Deep Genomics has identified therapeutic opportunities addressing hundreds of ...
DEEP GENOMICS EXPANDS LABORATORY, APPOINTS JOHAN FRANSSON AS HEAD OF PRECLINICAL RESEARCH
To support preclinical research and address the growing number of programs in our pipeline, Deep Genomics has expanded our experimental facility and appointed Johan Fransson.
TORONTO, Ontario, Canada – June 18, 2019. Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately.
Discovering Therapies for Neuromuscular Disorders
Deep Genomics to collaborate with Wave Life Sciences to discover novel therapies for genetic neuromuscular disorders
CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018 - Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., the leading AI therapeutics company that is building a ...
Taking on Metabolic & Neurodegenerative Disorders
Deep Genomics to identify oligonucleotide candidates for treating genetically defined metabolic and neurodegenerative disorders
For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.
TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using ...
$13M Invested in AI Platform for Genetic Medicines
Equity investment by Khosla Ventures, True Ventures and Bloomberg Beta will be used to direct platform to drug discovery
AI platform to unlock new classes of anti-sense oligonucleotide therapies.
TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the leading AI therapeutics company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by ...